LJPC-501
Phase 2Small molecule
LJPC-501 is one of 38 small molecule programs targeting Hepatorenal Syndrome. It is currently in Phase 2.
2
Indications
4
Total Trials
0
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
136 competitors in Hypotension
#DrugCompanyPhaseTrials
1Levophed
GGeneral Hospital of Ningxia Medical University
Phase 3
Firazyr
TakedaPhase 3
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Midodrine Hydrochloride
TakedaPhase 3
Precose
BayerPhase 2
Noradrenaline
IInstitute of Liver and Biliary Sciences, India
Phase 3
L-Carnitine
IIperboreal Pharma Srl
Phase 3
Bronitin Mist
LLongeveron Inc.
Phase 3
Voluven
RRegional Hospital Holstebro
Phase 3
Hemospan (MP4OX)
SSangart
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hypotension2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LJPC-501. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- LLa Jolla Pharmaceutical Company